NCT00346814 Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome
| NCT ID | NCT00346814 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Asociación para Evitar la Ceguera en México |
| Condition | Retinopathy of Prematurity |
| Study Type | INTERVENTIONAL |
| Enrollment | Not disclosed |
| Start Date | 2007-07 |
| Primary Completion | 2007-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Purpose:Retinopathy of prematurity (ROP) continues tobe a major cause of blindness in children. Although ablation of the retina with laser or cryotherapy reduces the incidence of blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role in the pathogenesis of ROP and inhibition of VEGF expression in the neovascular phase might prevent destructive neovascularization in ROP. The aim of this study is to determine the safety and efficacy of intravitreal bevacizumab in the treatment of retinopathy of prematurity
Eligibility Criteria
Inclusion Criteria: * Retinopathy of prematurity stages III, IV and V in which we can not treat with laser o cryotherAPY Exclusion Criteria: * PATIENTS THAT COULD BE TREATED WITH CRYOTHERAPY OR LASER
Contact & Investigator
Maria Martínez-Castellanos, MD
PRINCIPAL INVESTIGATOR
Asociación para Evitar la Ceguera en México
Frequently Asked Questions
Who can join the NCT00346814 clinical trial?
This trial is open to participants of all sexes, aged 1 Month or older, up to 12 Months, studying Retinopathy of Prematurity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT00346814 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT00346814 currently recruiting?
Yes, NCT00346814 is actively recruiting participants. Contact the research team at retinamex@yahoo.com for enrollment information.
Where is the NCT00346814 trial being conducted?
This trial is being conducted at Mexico City, Mexico.
Who is sponsoring the NCT00346814 clinical trial?
NCT00346814 is sponsored by Asociación para Evitar la Ceguera en México. The principal investigator is Maria Martínez-Castellanos, MD at Asociación para Evitar la Ceguera en México.